Qiagen (NYSE:QGEN) Reaches New 52-Week Low on Analyst Downgrade

Qiagen (NYSE:QGEN)’s share price reached a new 52-week low during trading on Monday after UBS Group lowered their price target on the stock from $50.00 to $48.00. UBS Group currently has a neutral rating on the stock. Qiagen traded as low as $39.63 and last traded at $39.97, with a volume of 363374 shares changing hands. The stock had previously closed at $41.34.

Several other brokerages have also recently commented on QGEN. Hsbc Global Res raised Qiagen to a “hold” rating in a research report on Thursday, October 17th. HSBC cut shares of Qiagen from a “buy” rating to a “hold” rating and set a $47.64 price objective for the company. in a research note on Thursday, October 17th. Jefferies Financial Group reiterated a “buy” rating and set a $52.50 target price (up from $40.83) on shares of Qiagen in a research report on Tuesday, December 10th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $46.67 price target (down previously from $48.61) on shares of Qiagen in a research report on Monday, January 6th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $48.78.

Institutional Investors Weigh In On Qiagen

A number of large investors have recently bought and sold shares of QGEN. GAMMA Investing LLC increased its position in Qiagen by 806.5% in the 3rd quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock valued at $26,000 after acquiring an additional 500 shares in the last quarter. Geneos Wealth Management Inc. increased its holdings in shares of Qiagen by 41.5% in the fourth quarter. Geneos Wealth Management Inc. now owns 856 shares of the company’s stock valued at $38,000 after purchasing an additional 251 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in Qiagen by 152.5% during the 4th quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company’s stock worth $39,000 after buying an additional 526 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new position in Qiagen in the 3rd quarter valued at $53,000. Finally, Smartleaf Asset Management LLC increased its stake in shares of Qiagen by 148.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company’s stock valued at $63,000 after buying an additional 835 shares during the period. 70.00% of the stock is currently owned by institutional investors.

Qiagen Trading Down 1.8 %

The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39. The company has a market cap of $8.73 billion, a P/E ratio of 109.55, a P/E/G ratio of 3.29 and a beta of 0.36. The business has a 50-day moving average price of $43.68 and a two-hundred day moving average price of $43.26.

Qiagen (NYSE:QGEN) last released its earnings results on Wednesday, February 5th. The company reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a return on equity of 13.97%. On average, analysts predict that Qiagen will post 2.28 EPS for the current year.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.